Position in CELC
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$12,063,228
-$3,225,816 QoQ
Shares Held
105,688
-31.1% QoQ
Ownership
0.217%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Walleye Capital LLC holds $278,324,471 across 103 Biotechnology names. CELC ranks #6 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMRN |
Biomarin Pharmaceutical Inc
|
364,246 | $20,576,256 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
228,593 | $16,975,316 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
87,365 | $16,516,353 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,752 | $13,731,998 | |
| 5 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
153,585 | $12,888,853 | |
| 6 | CELC |
Celcuity Inc.
This page
|
105,688 | $12,063,228 | |
| 7 | INSM |
INSMED Inc
|
71,819 | $11,743,842 | |
| 8 | SNDX |
Syndax Pharmaceuticals Inc
|
384,973 | $8,992,969 |
All Filings in CELC
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $12,063,228 | 105,688 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $15,289,044 | 153,289 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $14,765,709 | 298,901 | Shares | Sole | 2025-11-14 | |
| 2024-03-31 | $544,773 | 25,221 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||